Background: Immune activation predicts morbidity and mortality in treated HIV infection and may contribute to persistent gut epithelial barrier defects and systemic microbial translocation. We hypothesized that the luminally active anti-inflammatory agent, mesalamine, might decrease mucosal inflammation in treated HIV infection, leading to decreases in microbial translocation and systemic immune activation. Methodology: We performed a randomized placebo-controlled trial of mesalamine (Apriso) among HIV-infected individuals with incomplete CD4+ T cell recovery on suppressive antiretroviral therapy (ART). HIV-infected subjects with CD4 counts less than 350 cells/mm3 and undetectable plasma HIV RNA levels for greater than 1 year on ART were randomized to either mesalamine or placebo for 12 weeks followed by 12 weeks crossover to the other arm. Consenting subjects also participated in a serial rectal biopsy substudy. The primary outcome was the week 12 change in the percent of activated (CD38+ HLA-DR+) CD8+ T cells from baseline. Secondary outcome measures included changes in other immunologic markers in blood and gut as well as in markers of macro and microvascular function (flow-mediated dilatation [FMD] and hyperemic velocity). Results: Of 33 subjects (24 in the rectal biopsy substudy), 15 were randomized to receive mesalamine and 18 placebo in the first 12 weeks. Compared to placebo-treated subjects, mesalamine-treated subjects experienced a similar median change in the percent of activated peripheral blood CD8+ T cells from baseline to week 12 (+0.9% vs. -0.4%, P=0.63). There was also no evidence for a difference between groups in treatment-mediated changes in the percent of activated peripheral blood CD4+ T cells, rectal CD4+ and CD8+ T cells, or in plasma sCD14 (P=0.14), IL-6 (P=0.07), d-Dimer (P=0.27), kynurenine to tryptophan ratio (P=0.87), FMD, change in FMD or hyperemic velocity (P=0.73), or rectal HIV RNA or DNA levels. There was also no evidence for a change in immunologic markers during mesalamine therapy when those with early vs. late therapy were combined. Conclusions: Administration of a mesalamine preparation designed to release in the colonic mucosa does not significantly affect either systemic or colonic immune activation levels in HIV-infected individuals with incomplete CD4+ T cell recovery on suppressive ART. Alternative strategies to decrease microbial translocation and systemic immune activation are needed.